Correct Answer: B. IL-6
Tocilizumab is a humanized monoclonal antibody that selectively blocks the IL-6 receptor (both membrane-bound and soluble forms), preventing IL-6 signaling. IL-6 is a key pro-inflammatory cytokine produced by macrophages, fibroblasts, and T cells, driving systemic inflammation and acute phase response. In India, tocilizumab is approved for rheumatoid arthritis (RA), where IL-6 plays a central pathogenic role in joint inflammation and systemic manifestations. By inhibiting IL-6 signaling, tocilizumab reduces CRP, ESR, and joint damage progression. The drug is particularly valuable in Indian RA patients with inadequate response to conventional DMARDs or TNF inhibitors. Tocilizumab does not directly inhibit IL-2 (T cell growth factor), IL-5 (B cell/eosinophil differentiation), or IL-4 (Th2 response mediator). Its mechanism is receptor antagonism, not cytokine depletion, making it distinct from other biologic agents targeting different cytokine pathways.
Why the other options are wrong
A. IL-2 — IL-2 is a T cell-derived cytokine essential for T cell proliferation and activation. It is targeted by other agents (e.g., basiliximab, daclizumab in transplantation), not tocilizumab. NBE may trap students who confuse tocilizumab with other immunosuppressive biologics or recall IL-2 as a major inflammatory mediator without distinguishing which agent blocks which pathway. C. IL-5 — IL-5 is a Th2 cytokine critical for eosinophil differentiation and B cell maturation. Mepolizumab and reslizumab (anti-IL-5 agents) are used for severe eosinophilic asthma, not RA. This is a classic distractor for students who know biologics target interleukins but confuse which IL is blocked by which monoclonal antibody. D. IL-4 — IL-4 is a Th2-derived cytokine promoting IgE production and allergic responses. No approved monoclonal antibody directly targets IL-4 in clinical practice. Students may select this if they recall IL-4 as an immunomodulatory cytokine but lack specific knowledge of tocilizumab's IL-6 receptor antagonism mechanism.
High-Yield Facts
- Tocilizumab is a humanized monoclonal antibody against IL-6 receptor (not IL-6 itself), blocking both membrane-bound and soluble IL-6R.
- IL-6 is the primary pro-inflammatory cytokine in RA pathogenesis; tocilizumab reduces CRP, ESR, and joint damage in Indian RA patients.
- Tocilizumab is approved in India for moderate-to-severe RA refractory to conventional DMARDs or TNF inhibitors (as per RNTCP/IAP guidelines).
- IL-2 is targeted by basiliximab/daclizumab (transplant rejection); IL-5 by mepolizumab (eosinophilic asthma); IL-4 has no approved monoclonal antagonist.
- Tocilizumab mechanism is receptor antagonism, not cytokine depletion, distinguishing it from TNF inhibitors or other biologic pathways.
Mnemonics
IL-6 Receptor Blocker = Tocilizumab (TIL-6) Tocilizumab → IL-6 receptor. Remember: 'T' for 'Target IL-6.' Used in RA when TNF inhibitors fail. Biologic Targets by Interleukin IL-2: Basiliximab (transplant) | IL-5: Mepolizumab (asthma) | IL-6: Tocilizumab (RA) | TNF-α: Infliximab/Adalimumab (RA/IBD). Each IL, one agent.
NBE Trap
NBE pairs tocilizumab with multiple interleukins (IL-2, IL-4, IL-5, IL-6) to test whether students know the specific receptor target of this agent. Students who recall "tocilizumab is a biologic for RA" but lack mechanistic knowledge may guess IL-2 (a classic inflammatory cytokine) or IL-5 (another monoclonal target), missing the IL-6 receptor antagonism.
Clinical Pearl
In Indian RA clinics, tocilizumab is increasingly used as a second-line biologic after TNF inhibitor failure or intolerance. Monitoring IL-6 levels and acute phase reactants (CRP, ESR) helps assess response; rapid normalization of CRP often precedes clinical remission, making it a useful bedside marker for treatment efficacy.
_Reference: KD Tripathi Pharmacology Ch. 49 (Immunosuppressants & Biologics); Harrison Ch. 297 (Rheumatoid Arthritis)_